X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4114) 4114
thiazoles - adverse effects (2525) 2525
male (2352) 2352
thiazoles - therapeutic use (2126) 2126
female (2060) 2060
middle aged (1410) 1410
adult (1399) 1399
animals (1311) 1311
thiazoles - administration & dosage (1096) 1096
aged (961) 961
thiazoles - pharmacology (953) 953
pharmacology & pharmacy (901) 901
treatment outcome (745) 745
dose-response relationship, drug (563) 563
piperazines - therapeutic use (549) 549
piperazines - adverse effects (528) 528
antipsychotic agents - adverse effects (474) 474
double-blind method (466) 466
psychiatry (461) 461
dasatinib (447) 447
antipsychotic agents - therapeutic use (441) 441
rats (432) 432
thiazoles - pharmacokinetics (425) 425
thiazolidinediones (416) 416
adolescent (404) 404
double-blind (387) 387
administration, oral (379) 379
mice (379) 379
thiazoles (377) 377
drug therapy (340) 340
oncology (332) 332
time factors (331) 331
efficacy (330) 330
analysis (327) 327
care and treatment (312) 312
schizophrenia (302) 302
schizophrenia - drug therapy (302) 302
drug therapy, combination (296) 296
pyrimidines - therapeutic use (291) 291
aged, 80 and over (290) 290
pyrimidines - adverse effects (289) 289
medicine, general & internal (286) 286
meloxicam (286) 286
hypoglycemic agents - adverse effects (281) 281
young adult (280) 280
neurosciences (276) 276
diabetes mellitus, type 2 - drug therapy (272) 272
safety (270) 270
research (266) 266
dermatology (265) 265
risk factors (264) 264
dermatitis, allergic contact - etiology (263) 263
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (260) 260
clinical neurology (257) 257
pharmacokinetics (255) 255
hypoglycemic agents - therapeutic use (253) 253
ziprasidone (251) 251
allergy (250) 250
hematology (246) 246
medicine & public health (246) 246
clinical trials as topic (239) 239
imatinib mesylate (233) 233
drug administration schedule (229) 229
toxicology (229) 229
thiazines - adverse effects (228) 228
drug interactions (223) 223
benzothiazoles (219) 219
anti-inflammatory agents, non-steroidal - adverse effects (218) 218
tetrazolium salts (217) 217
therapy (217) 217
protein kinase inhibitors - therapeutic use (212) 212
pyridines - adverse effects (203) 203
thiazoles - chemistry (201) 201
in-vitro (196) 196
piperazines - administration & dosage (196) 196
cancer (193) 193
thiazines - therapeutic use (191) 191
clinical trials (189) 189
preservatives, pharmaceutical - adverse effects (189) 189
protein kinase inhibitors - adverse effects (189) 189
child (187) 187
olanzapine (186) 186
patch tests (186) 186
randomized controlled trials as topic (185) 185
antineoplastic agents - therapeutic use (184) 184
thiazines - administration & dosage (180) 180
pyridines - therapeutic use (179) 179
troglitazone (179) 179
dosage and administration (177) 177
pyridines - administration & dosage (177) 177
toxicity (175) 175
retrospective studies (171) 171
abridged index medicus (168) 168
health aspects (168) 168
benzamides (165) 165
expression (164) 164
chromans - adverse effects (161) 161
internal medicine (161) 161
pharmacology/toxicology (161) 161
cell survival - drug effects (160) 160
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4805) 4805
German (79) 79
Japanese (77) 77
French (41) 41
Spanish (27) 27
Russian (22) 22
Italian (15) 15
Chinese (14) 14
Danish (10) 10
Hungarian (9) 9
Polish (9) 9
Dutch (8) 8
Portuguese (8) 8
Norwegian (3) 3
Swedish (2) 2
Bulgarian (1) 1
Croatian (1) 1
Czech (1) 1
Lithuanian (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Circulation, ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
.... In addition to familiarity with the dosing and monitoring of vitamin K antagonists, clinicians are accustomed to using vitamin K if there is a need to reverse the anticoagulant effect of vitamin K antagonists... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 7, pp. 581 - 589
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 08/2017, Volume 2019, Issue 10, p. CD012537
Background Pain is a common feature of childhood and adolescence around the world, and for many young people, that pain is chronic. The World Health... 
2019 3.6 All/Other/Non‐cancer chronic pain | Management in children | Anti‐Inflammatory Agents, Non‐Steroidal | Methoxsalen | 2019 3. Chronic pain | Lactones | Arthritis, Juvenile | Chronic non‐cancer pain management | Naproxen | Ibuprofen | Thiazoles | Child health | Management and prevention of chronic non‐cancer pain in children | Sulfones | Chronic Pain | Fenoprofen | Meloxicam | Aspirin | Thiazines | Celecoxib | Pain & anaesthesia | Arthritis, Rheumatoid | Randomized Controlled Trials as Topic | Chronic non‐cancer pain | Medicine General & Introductory Medical Sciences | Chronic Disease | IBUPROFEN | MEDICINE, GENERAL & INTERNAL | EFFICACY | FIBROMYALGIA | SAFETY | TREATMENT OUTCOMES | JUVENILE RHEUMATOID-ARTHRITIS | CLINICAL-TRIALS | GRADE | NAPROXEN | SHORT-TERM | Ibuprofen - therapeutic use | Sulfones - therapeutic use | Thiazines - therapeutic use | Humans | Thiazines - adverse effects | Sulfones - adverse effects | Child, Preschool | Thiazoles - therapeutic use | Thiazoles - adverse effects | Arthritis, Juvenile - drug therapy | Fenoprofen - therapeutic use | Arthritis, Rheumatoid - drug therapy | Aspirin - adverse effects | Aspirin - therapeutic use | Fenoprofen - adverse effects | Child | Celecoxib - adverse effects | Naproxen - adverse effects | Chronic Pain - drug therapy | Celecoxib - therapeutic use | Lactones - adverse effects | Methoxsalen - therapeutic use | Naproxen - therapeutic use | Lactones - therapeutic use | Methoxsalen - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Adolescent | Ibuprofen - adverse effects
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
Nature (London), ISSN 1476-4687, 2015, Volume 521, Issue 7550, pp. 74 - 76
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 11/2017, Volume 2017, Issue 11, p. CD011373
Background Chronic kidney disease (CKD) is an independent risk factor for atrial fibrillation (AF), which is more prevalent among CKD patients than the general... 
Kidney disease | Anticoagulants | Pyridines | Renal Insufficiency, Chronic | Stroke | Warfarin | Administration, Oral | Pyrazoles | Pyridones | Chronic kidney disease | Dabigatran | Hemorrhage | Embolism | Randomized Controlled Trials as Topic | Arrythmias | Rivaroxaban | Cardiovascular risk management | Antithrombins | Thiazoles | Heart & circulation | General management | Medicine General & Introductory Medical Sciences | Atrial Fibrillation | EAST-ASIAN PATIENTS | MEDICINE, GENERAL & INTERNAL | J-ROCKET AF | XA NEXT-GENERATION | TRANSIENT ISCHEMIC ATTACK | AF-TIMI 48 | VITAMIN-K ANTAGONISM | RIVAROXABAN VS. WARFARIN | LY RANDOMIZED EVALUATION | PERIPHERAL ARTERY-DISEASE | SEVERE RENAL IMPAIRMENT | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Warfarin - adverse effects | Renal Insufficiency, Chronic - complications | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Thiazoles - adverse effects | Warfarin - therapeutic use | Pyridines - adverse effects | Rivaroxaban - adverse effects | Rivaroxaban - therapeutic use | Pyrazoles - adverse effects | Pyridines - therapeutic use | Stroke - prevention & control | Embolism - prevention & control | Hemorrhage - epidemiology | Antithrombins - therapeutic use | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Antithrombins - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects
Journal Article